{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:15:52Z","timestamp":1793693752523,"version":"4.5.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Multiple myeloma (MM) remains an incurable disease despite therapeutic advancements extending survival. Relapses driven by drug resistance and minimal residual disease underscore the need for novel treatment strategies. Natural Killer (NK) cells play a key role in MM immunity, yet their function is suppressed by inhibitory cytokines and metabolites from the tumor microenvironment. Developing anticancer drugs with immunomodulatory properties, such as enhancing tumor sensitivity to NK cell recognition, remains a critical challenge. MM cells exhibit high protein synthesis rates, making them vulnerable to proteostasis disruption. Dysregulated ribosome function and aberrant mRNA translation contribute to proteasome inhibitor resistance. RNA Polymerase I (RNA Pol I)-mediated rDNA transcription, the rate-limiting step in ribosome biogenesis (RiBi), is significantly upregulated in MM. Targeting rDNA transcription and inducing nucleolar stress response (NSR) presents a promising therapeutic approach, though its immunomodulatory role is not well understood. Our study examined two \u201cfirst-in-cla\n                    <jats:italic>ss<\/jats:italic>\n                    \u201d RNA Pol I inhibitors, CX-5461 and BMH-21, which differentially regulate NK cell-activating and inhibitory ligand expression in MM. BMH-21 enhanced NK cell degranulation and increased IFN-\u03b3 and TNF-\u03b1 secretion, demonstrating stronger immunostimulatory effects than CX-5461. Conversely, CX-5461 induced a significant DNA damage response (DDR) and senescence, leading to HLA-E upregulation and suppressing NK cell activity. Mechanistic analyses revealed that HLA-E presentation is governed by ATR\/AKT\/mTORC1\/S6K signaling and Pioneer Round of Translation (PRT), linking its regulation to DDR. This effect was modulated by Lenalidomide and Panobinostat. Moreover, RNA Pol I inhibition enhanced Daratumumab-mediated antibody-dependent cellular cytotoxicity (ADCC) of NK cells against MM, uncovering novel immuno-mediated antitumor mechanisms.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08196-6","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:50:00Z","timestamp":1764341400000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"given":"Elena","family":"Sproviero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Gnocchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Cipollone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Petillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cassone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2904-6371","authenticated-orcid":false,"given":"Rosa","family":"Molfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0906-1566","authenticated-orcid":false,"given":"Alessandra","family":"Zingoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5461-9026","authenticated-orcid":false,"given":"Alessandra","family":"Soriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Cerboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Petrucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4187-8912","authenticated-orcid":false,"given":"Francesca","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7605-1531","authenticated-orcid":false,"given":"Rossella","family":"Paolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-1417","authenticated-orcid":false,"given":"Gabriella","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-538X","authenticated-orcid":false,"given":"Marco","family":"Cippitelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"8196_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13020226","volume":"13","author":"T Pazina","year":"2021","unstructured":"Pazina T, MacFarlane AWt, Bernabei L, Dulaimi E, Kotcher R, Yam C, et al. Alterations of NK Cell phenotype in the disease course of multiple myeloma. Cancers. 2021;13:1\u201322.","journal-title":"Cancers"},{"key":"8196_CR2","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s40164-024-00578-4","volume":"13","author":"K Bisht","year":"2024","unstructured":"Bisht K, Merino A, Igarashi R, Gauthier L, Chiron M, Desjonqueres A, et al. Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities. Exp Hematol Oncol. 2024;13:114.","journal-title":"Exp Hematol Oncol"},{"key":"8196_CR3","first-page":"495","volume":"9","author":"LL Lanier","year":"2008","unstructured":"Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. NatImmunol. 2008;9:495\u2013502.","journal-title":"NatImmunol"},{"key":"8196_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-020711-075005","volume":"31","author":"EO Long","year":"2013","unstructured":"Long EO, Kim HS, Liu D, Peterson ME, Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol. 2013;31:227\u201358.","journal-title":"Annu Rev Immunol"},{"key":"8196_CR5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA. Allogeneic natural killer cell therapy. Blood. 2023;141:856\u201368.","journal-title":"Blood"},{"key":"8196_CR6","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41568-022-00491-0","volume":"22","author":"TJ Laskowski","year":"2022","unstructured":"Laskowski TJ, Biederstadt A, Rezvani K. Natural killer cells in antitumour adoptive cell immunotherapy. Nat Rev Cancer. 2022;22:557\u201375.","journal-title":"Nat Rev Cancer"},{"key":"8196_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/icb.2017.6","volume":"95","author":"MC Ochoa","year":"2017","unstructured":"Ochoa MC, Minute L, Rodriguez I, Garasa S, Perez-Ruiz E, Inoges S, et al. Antibody-dependent cell cytotoxicity: immunotherapy strategies enhancing effector NK cells. Immunol Cell Biol. 2017;95:347\u201355.","journal-title":"Immunol Cell Biol"},{"key":"8196_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.omto.2021.10.001","volume":"23","author":"KP Fabian","year":"2021","unstructured":"Fabian KP, Hodge JW. The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy. Mol Ther Oncolytics. 2021;23:266\u201376.","journal-title":"Mol Ther Oncolytics"},{"key":"8196_CR9","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1053\/j.seminoncol.2022.01.004","volume":"49","author":"JA Clara","year":"2022","unstructured":"Clara JA, Childs RW. Harnessing natural killer cells for the treatment of multiple myeloma. Semin Oncol. 2022;49:69\u201385.","journal-title":"Semin Oncol"},{"key":"8196_CR10","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers JA, Miller JS. Exploring the NK cell platform for cancer immunotherapy. Nat Rev Clin Oncol. 2021;18:85\u2013100.","journal-title":"Nat Rev Clin Oncol"},{"key":"8196_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-023-06945-1","volume":"626","author":"E Vivier","year":"2024","unstructured":"Vivier E, Rebuffet L, Narni-Mancinelli E, Cornen S, Igarashi RY, Fantin VR. Natural killer cell therapies. Nature. 2024;626:727\u201336.","journal-title":"Nature"},{"key":"8196_CR12","doi-asserted-by":"publisher","first-page":"178698","DOI":"10.1155\/2015\/178698","volume":"2015","author":"C Fionda","year":"2015","unstructured":"Fionda C, Soriani A, Zingoni A, Santoni A, Cippitelli M. NKG2D and DNAM-1 ligands: molecular targets for NK cell-mediated immunotherapeutic intervention in multiple myeloma. BioMed Res Int. 2015;2015:178698.","journal-title":"BioMed Res Int"},{"key":"8196_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ctrv.2018.10.005","volume":"70","author":"C Fionda","year":"2018","unstructured":"Fionda C, Stabile H, Molfetta R, Soriani A, Bernardini G, Zingoni A, et al. Translating the anti-myeloma activity of Natural Killer cells into clinical application. Cancer Treat Rev. 2018;70:255\u201364.","journal-title":"Cancer Treat Rev"},{"key":"8196_CR14","doi-asserted-by":"publisher","first-page":"e26663","DOI":"10.4161\/onci.26663","volume":"2","author":"A Soriani","year":"2013","unstructured":"Soriani A, Fionda C, Ricci B, Iannitto ML, Cippitelli M, Santoni A. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. Oncoimmunology. 2013;2:e26663.","journal-title":"Oncoimmunology"},{"key":"8196_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16393-4","volume":"11","author":"E Sanij","year":"2020","unstructured":"Sanij E, Hannan KM, Xuan J, Yan S, Ahern JE, Trigos AS, et al. CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nat Commun. 2020;11:2641.","journal-title":"Nat Commun"},{"key":"8196_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17923-4","volume":"12","author":"L Snyers","year":"2022","unstructured":"Snyers L, Laffer S, Lohnert R, Weipoltshammer K, Schofer C. CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response. Sci Rep. 2022;12:13972.","journal-title":"Sci Rep"},{"key":"8196_CR17","doi-asserted-by":"publisher","first-page":"568","DOI":"10.3389\/fcell.2020.00568","volume":"8","author":"J Son","year":"2020","unstructured":"Son J, Hannan KM, Poortinga G, Hein N, Cameron DP, Ganley ARD, et al. rDNA chromatin activity status as a biomarker of sensitivity to the RNA polymerase i transcription inhibitor CX-5461. Front Cell Dev Biol. 2020;8:568.","journal-title":"Front Cell Dev Biol"},{"key":"8196_CR18","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.18632\/oncotarget.2020","volume":"5","author":"L Colis","year":"2014","unstructured":"Colis L, Peltonen K, Sirajuddin P, Liu H, Sanders S, Ernst G, et al. DNA intercalator BMH-21 inhibits RNA polymerase I independent of DNA damage response. Oncotarget. 2014;5:4361\u20139.","journal-title":"Oncotarget"},{"key":"8196_CR19","doi-asserted-by":"publisher","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","volume":"95","author":"N Lee","year":"1998","unstructured":"Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A. Proc Natl Acad Sci USA. 1998;95:5199\u2013204.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8196_CR20","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","volume":"175","author":"P Andre","year":"2018","unstructured":"Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731\u201343.e1713.","journal-title":"Cell"},{"key":"8196_CR21","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1084\/jem.185.4.795","volume":"185","author":"AG Brooks","year":"1997","unstructured":"Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J Exp Med. 1997;185:795\u2013800.","journal-title":"J Exp Med"},{"key":"8196_CR22","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/BF02786361","volume":"16","author":"M Lopez-Botet","year":"1997","unstructured":"Lopez-Botet M, Carretero M, Perez-Villar J, Bellon T, Llano M, Navarro F. The CD94\/NKG2 C-type lectin receptor complex: involvement in NK cell-mediated recognition of HLA class I molecules. Immunol Res. 1997;16:175\u201385.","journal-title":"Immunol Res"},{"key":"8196_CR23","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1093\/emboj\/18.15.4250","volume":"18","author":"M Vales-Gomez","year":"1999","unstructured":"Vales-Gomez M, Reyburn HT, Erskine RA, Lopez-Botet M, Strominger JL. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94\/NKG2-A and the activating receptor CD94\/NKG2-C to HLA-E. EMBO J. 1999;18:4250\u201360.","journal-title":"EMBO J"},{"key":"8196_CR24","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/eji.1830270517","volume":"27","author":"V Braud","year":"1997","unstructured":"Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol. 1997;27:1164\u20139.","journal-title":"Eur J Immunol"},{"key":"8196_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molimm.2020.02.011","volume":"120","author":"EJ Grant","year":"2020","unstructured":"Grant EJ, Nguyen AT, Lobos CA, Szeto C, Chatzileontiadou DSM, Gras S. The unconventional role of HLA-E: The road less traveled. Mol Immunol. 2020;120:101\u201312.","journal-title":"Mol Immunol"},{"key":"8196_CR26","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1084\/jem.20020797","volume":"196","author":"J Michaelsson","year":"2002","unstructured":"Michaelsson J, Teixeira de Matos C, Achour A, Lanier LL, Karre K, Soderstrom K. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94\/NKG2A recognition. J Exp Med. 2002;196:1403\u201314.","journal-title":"J Exp Med"},{"key":"8196_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40220-1","volume":"14","author":"BD Huisman","year":"2023","unstructured":"Huisman BD, Guan N, Ruckert T, Garner L, Singh NK, McMichael AJ, et al. High-throughput characterization of HLA-E-presented CD94\/NKG2x ligands reveals peptides which modulate NK cell activation. Nat Commun. 2023;14:4809.","journal-title":"Nat Commun"},{"key":"8196_CR28","doi-asserted-by":"publisher","first-page":"11572","DOI":"10.1073\/pnas.1104104108","volume":"108","author":"S Apcher","year":"2011","unstructured":"Apcher S, Daskalogianni C, Lejeune F, Manoury B, Imhoos G, Heslop L, et al. Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translation. Proc Natl Acad Sci USA. 2011;108:11572\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8196_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.molimm.2015.04.019","volume":"68","author":"S Apcher","year":"2015","unstructured":"Apcher S, Daskalogianni C, Fahraeus R. Pioneer translation products as an alternative source for MHC-I antigenic peptides. Mol Immunol. 2015;68:68\u201371.","journal-title":"Mol Immunol"},{"key":"8196_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1080\/14712598.2017.1322578","volume":"17","author":"C Touzeau","year":"2017","unstructured":"Touzeau C, Moreau P. Daratumumab for the treatment of multiple myeloma. Expert Opin Biol Ther. 2017;17:887\u201393.","journal-title":"Expert Opin Biol Ther"},{"key":"8196_CR31","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1:2105\u201314.","journal-title":"Blood Adv"},{"key":"8196_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","volume":"6","author":"J Kang","year":"2021","unstructured":"Kang J, Brajanovski N, Chan KT, Xuan J, Pearson RB, Sanij E. Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduct Target Ther. 2021;6:323.","journal-title":"Signal Transduct Target Ther"},{"key":"8196_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1158\/2159-8290.CD-14-0673","volume":"6","author":"JR Devlin","year":"2016","unstructured":"Devlin JR, Hannan KM, Hein N, Cullinane C, Kusnadi E, Ng PY, et al. Combination therapy targeting ribosome biogenesis and mRNA translation synergistically extends survival in MYC-driven lymphoma. Cancer Discov. 2016;6:59\u201370.","journal-title":"Cancer Discov"},{"key":"8196_CR34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/bjh.14525","volume":"177","author":"HC Lee","year":"2017","unstructured":"Lee HC, Wang H, Baladandayuthapani V, Lin H, He J, Jones RJ, et al. RNA polymerase I inhibition with CX-5461 as a novel therapeutic strategy to target MYC in multiple myeloma. Br J Haematol. 2017;177:80\u201394.","journal-title":"Br J Haematol"},{"key":"8196_CR35","doi-asserted-by":"publisher","first-page":"18094","DOI":"10.18632\/oncotarget.4093","volume":"6","author":"SS Negi","year":"2015","unstructured":"Negi SS, Brown P. rRNA synthesis inhibitor, CX-5461, activates ATM\/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis. Oncotarget. 2015;6:18094\u2013104.","journal-title":"Oncotarget"},{"key":"8196_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26640-x","volume":"12","author":"M Pan","year":"2021","unstructured":"Pan M, Wright WC, Chapple RH, Zubair A, Sandhu M, Batchelder JE, et al. The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma. Nat Commun. 2021;12:6468.","journal-title":"Nat Commun"},{"key":"8196_CR37","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41416-020-01158-z","volume":"124","author":"S Yan","year":"2021","unstructured":"Yan S, Xuan J, Brajanovski N, Tancock MRC, Madhamshettiwar PB, Simpson KJ, et al. The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. Br J Cancer. 2021;124:616\u201327.","journal-title":"Br J Cancer"},{"key":"8196_CR38","doi-asserted-by":"publisher","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-16-0124","volume":"22","author":"RJ Rebello","year":"2016","unstructured":"Rebello RJ, Kusnadi E, Cameron DP, Pearson HB, Lesmana A, Devlin JR, et al. The dual inhibition of RNA Pol I transcription and PIM kinase as a new therapeutic approach to treat advanced prostate cancer. Clin Cancer Res: J Am Assoc Cancer Res. 2016;22:5539\u201352.","journal-title":"Clin Cancer Res: J Am Assoc Cancer Res"},{"key":"8196_CR39","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1158\/1535-7163.MCT-20-0932","volume":"20","author":"MG Lawrence","year":"2021","unstructured":"Lawrence MG, Porter LH, Choo N, Pook D, Grummet JP, Pezaro CJ, et al. CX-5461 sensitizes DNA damage repair-proficient castrate-resistant prostate cancer to PARP inhibition. Mol Cancer Ther. 2021;20:2140\u201350.","journal-title":"Mol Cancer Ther"},{"key":"8196_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ccr.2012.05.019","volume":"22","author":"MJ Bywater","year":"2012","unstructured":"Bywater MJ, Poortinga G, Sanij E, Hein N, Peck A, Cullinane C, et al. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. Cancer cell. 2012;22:51\u201365.","journal-title":"Cancer cell"},{"key":"8196_CR41","doi-asserted-by":"publisher","first-page":"2882","DOI":"10.1182\/blood-2016-05-718171","volume":"129","author":"N Hein","year":"2017","unstructured":"Hein N, Cameron DP, Hannan KM, Nguyen NN, Fong CY, Sornkom J, et al. Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood. 2017;129:2882\u201395.","journal-title":"Blood"},{"key":"8196_CR42","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1158\/2159-8290.CD-18-1455","volume":"9","author":"A Khot","year":"2019","unstructured":"Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, et al. First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: results of a phase I dose-escalation study. Cancer Discov. 2019;9:1036\u201349.","journal-title":"Cancer Discov"},{"key":"8196_CR43","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrc.2017.104","volume":"18","author":"J Pelletier","year":"2018","unstructured":"Pelletier J, Thomas G, Volarevic S. Ribosome biogenesis in cancer: new players and therapeutic avenues. Nat Rev Cancer. 2018;18:51\u201363.","journal-title":"Nat Rev Cancer"},{"key":"8196_CR44","doi-asserted-by":"publisher","first-page":"e37227","DOI":"10.1016\/j.heliyon.2024.e37227","volume":"10","author":"T Liu","year":"2024","unstructured":"Liu T, Pan G, Zhang J, Wang J, Guo X, Chen Y, et al. Molecular basis of CX-5461-induced DNA damage response in primary vascular smooth muscle cells. Heliyon. 2024;10:e37227.","journal-title":"Heliyon"},{"key":"8196_CR45","doi-asserted-by":"publisher","first-page":"4053","DOI":"10.1073\/pnas.1921649117","volume":"117","author":"PM Bruno","year":"2020","unstructured":"Bruno PM, Lu M, Dennis KA, Inam H, Moore CJ, Sheehe J, et al. The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning. Proc Natl Acad Sci USA. 2020;117:4053\u201360.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8196_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/molecules24244445","volume":"24","author":"B El Hassouni","year":"2019","unstructured":"El Hassouni B, Mantini G, Immordino B, Peters GJ, Giovannetti E, et al. CX-5461 Inhibits Pancreatic Ductal Adenocarcinoma Cell Growth, Migration and Induces DNA Damage. Molecules. 2019;24:1\u201311.","journal-title":"Molecules"},{"key":"8196_CR47","doi-asserted-by":"publisher","first-page":"49800","DOI":"10.18632\/oncotarget.10452","volume":"7","author":"J Quin","year":"2016","unstructured":"Quin J, Chan KT, Devlin JR, Cameron DP, Diesch J, Cullinane C, et al. Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM\/ATR signaling. Oncotarget. 2016;7:49800\u201318.","journal-title":"Oncotarget"},{"key":"8196_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines12071514","volume":"12","author":"DP Cameron","year":"2024","unstructured":"Cameron DP, Sornkom J, Alsahafi S, Drygin D, Poortinga G, McArthur GA, et al. CX-5461 preferentially induces Top2alpha-dependent DNA breaks at ribosomal DNA loci. Biomedicines. 2024;12:1\u201321.","journal-title":"Biomedicines"},{"key":"8196_CR49","doi-asserted-by":"publisher","first-page":"23609","DOI":"10.18632\/oncotarget.4603","volume":"6","author":"C Fionda","year":"2015","unstructured":"Fionda C, Abruzzese MP, Zingoni A, Cecere F, Vulpis E, Peruzzi G, et al. The IMiDs targets IKZF-1\/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. Oncotarget. 2015;6:23609\u201330.","journal-title":"Oncotarget"},{"key":"8196_CR50","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.4049\/jimmunol.1201426","volume":"190","author":"C Fionda","year":"2013","unstructured":"Fionda C, Malgarini G, Soriani A, Zingoni A, Cecere F, Iannitto ML, et al. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. J Immunol. 2013;190:6662\u201372.","journal-title":"J Immunol"},{"key":"8196_CR51","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/nri3174","volume":"12","author":"E Vivier","year":"2012","unstructured":"Vivier E, Ugolini S, Blaise D, Chabannon C, Brossay L. Targeting natural killer cells and natural killer T cells in cancer. Nat Rev Immunol. 2012;12:239\u201352.","journal-title":"Nat Rev Immunol"},{"key":"8196_CR52","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3389\/fimmu.2019.01179","volume":"10","author":"D Pende","year":"2019","unstructured":"Pende D, Falco M, Vitale M, Cantoni C, Vitale C, Munari E, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol. 2019;10:1179.","journal-title":"Front Immunol"},{"key":"8196_CR53","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1172\/JCI123955","volume":"129","author":"T Kamiya","year":"2019","unstructured":"Kamiya T, Seow SV, Wong D, Robinson M, Campana D. Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Investig. 2019;129:2094\u2013106.","journal-title":"J Clin Investig"},{"key":"8196_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines10121993","volume":"10","author":"JG Fisher","year":"2022","unstructured":"Fisher JG, Doyle ADP, Graham LV, Khakoo SI, Blunt MD, et al. Disruption of the NKG2A:HLA-E immune checkpoint axis to enhance NK cell activation against cancer. Vaccines. 2022;10:1\u201317.","journal-title":"Vaccines"},{"key":"8196_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jitc-2024-009934","volume":"12","author":"Y Li","year":"2024","unstructured":"Li Y, Li Z, Tang Y, Zhuang X, Feng W, Boor PPC, et al. Unlocking the therapeutic potential of the NKG2A-HLA-E immune checkpoint pathway in T cells and NK cells for cancer immunotherapy. J Immunother Cancer. 2024;12:1\u201317.","journal-title":"J Immunother Cancer"},{"key":"8196_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00943-2","volume":"13","author":"M Ozga","year":"2023","unstructured":"Ozga M, Zhao Q, Huric L, Miller C, Rosko A, Khan A, et al. Concomitant 1q+ and t(4;14) influences disease characteristics, immune system, and prognosis in double-hit multiple myeloma. Blood Cancer J. 2023;13:167.","journal-title":"Blood Cancer J"},{"key":"8196_CR57","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2004-04-1422","volume":"105","author":"E Carbone","year":"2005","unstructured":"Carbone E, Neri P, Mesuraca M, Fulciniti MT, Otsuki T, Pende D, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105:251\u20138.","journal-title":"Blood"},{"key":"8196_CR58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339.","journal-title":"Cancer Discov"},{"key":"8196_CR59","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature23470","volume":"548","author":"SM Harding","year":"2017","unstructured":"Harding SM, Benci JL, Irianto J, Discher DE, Minn AJ, Greenberg RA. Mitotic progression following DNA damage enables pattern recognition within micronuclei. Nature. 2017;548:466\u201370.","journal-title":"Nature"},{"key":"8196_CR60","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nature23449","volume":"548","author":"KJ Mackenzie","year":"2017","unstructured":"Mackenzie KJ, Carroll P, Martin CA, Murina O, Fluteau A, Simpson DJ, et al. cGAS surveillance of micronuclei links genome instability to innate immunity. Nature. 2017;548:461\u20135.","journal-title":"Nature"},{"key":"8196_CR61","doi-asserted-by":"publisher","first-page":"e32542","DOI":"10.1371\/journal.pone.0032542","volume":"7","author":"S Wan","year":"2012","unstructured":"Wan S, Pestka S, Jubin RG, Lyu YL, Tsai YC, Liu LF. Chemotherapeutics and radiation stimulate MHC class I expression through elevated interferon-beta signaling in breast cancer cells. PLoS ONE. 2012;7:e32542.","journal-title":"PLoS ONE"},{"key":"8196_CR62","doi-asserted-by":"publisher","first-page":"103590","DOI":"10.1016\/j.dnarep.2023.103590","volume":"132","author":"Y Uchihara","year":"2023","unstructured":"Uchihara Y, Shibata A. Regulation of DNA damage-induced HLA class I presentation. DNA Repair. 2023;132:103590.","journal-title":"DNA Repair"},{"key":"8196_CR63","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1016\/j.molcel.2022.04.030","volume":"82","author":"Y Uchihara","year":"2022","unstructured":"Uchihara Y, Permata TBM, Sato H, Kawabata-Iwakawa R, Katada S, Gu W, et al. DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production. Mol Cell. 2022;82:2557\u201370.e2557.","journal-title":"Mol Cell"},{"key":"8196_CR64","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cell.2010.07.022","volume":"142","author":"LE Maquat","year":"2010","unstructured":"Maquat LE, Tarn WY, Isken O. The pioneer round of translation: features and functions. Cell. 2010;142:368\u201374.","journal-title":"Cell"},{"key":"8196_CR65","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.cell.2008.02.031","volume":"133","author":"XM Ma","year":"2008","unstructured":"Ma XM, Yoon SO, Richardson CJ, Julich K, Blenis J. SKAR links pre-mRNA splicing to mTOR\/S6K1-mediated enhanced translation efficiency of spliced mRNAs. Cell. 2008;133:303\u201313.","journal-title":"Cell"},{"key":"8196_CR66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ymeth.2018.12.005","volume":"155","author":"T Kurosaki","year":"2019","unstructured":"Kurosaki T, Myers JR, Maquat LE. Defining nonsense-mediated mRNA decay intermediates in human cells. Methods. 2019;155:68\u201376.","journal-title":"Methods"},{"key":"8196_CR67","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/s41580-019-0126-2","volume":"20","author":"T Kurosaki","year":"2019","unstructured":"Kurosaki T, Popp MW, Maquat LE. Quality and quantity control of gene expression by nonsense-mediated mRNA decay. Nat Rev Mol Cell Biol. 2019;20:406\u201320.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"8196_CR68","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","volume":"34","author":"A Kahles","year":"2018","unstructured":"Kahles A, Lehmann KV, Toussaint NC, Huser M, Stark SG, Sachsenberg T, et al. Comprehensive analysis of alternative splicing across tumors from 8,705 patients. Cancer Cell. 2018;34:211\u201324.e216.","journal-title":"Cancer Cell"},{"key":"8196_CR69","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/ncb1337","volume":"8","author":"A Jazayeri","year":"2006","unstructured":"Jazayeri A, Falck J, Lukas C, Bartek J, Smith GC, Lukas J, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol. 2006;8:37\u201345.","journal-title":"Nat Cell Biol"},{"key":"8196_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10335-5","volume":"10","author":"BI Pereira","year":"2019","unstructured":"Pereira BI, Devine OP, Vukmanovic-Stejic M, Chambers ES, Subramanian P, Patel N, et al. Senescent cells evade immune clearance via HLA-E-mediated NK and CD8(+) T cell inhibition. Nat Commun. 2019;10:2387.","journal-title":"Nat Commun"},{"key":"8196_CR71","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.","journal-title":"Leukemia"},{"key":"8196_CR72","doi-asserted-by":"publisher","first-page":"200771","DOI":"10.1016\/j.omton.2024.200771","volume":"32","author":"KH Maclachlan","year":"2024","unstructured":"Maclachlan KH, Gitareja K, Kang J, Cuddihy A, Cao Y, Hein N, et al. Targeting the ribosome to treat multiple myeloma. Mol Ther Oncol. 2024;32:200771.","journal-title":"Mol Ther Oncol"},{"key":"8196_CR73","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/cncr.32065","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, et al. Daratumumab in multiple myeloma. Cancer. 2019;125:2364\u201382.","journal-title":"Cancer"},{"key":"8196_CR74","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1080\/17474086.2023.2246651","volume":"16","author":"S Yadav","year":"2023","unstructured":"Yadav S, Gundeti S, Bhave A, Deb U, Dixit J, Mishra K. Role of daratumumab in the frontline management of multiple myeloma: a narrative review. Expert Rev Hematol. 2023;16:743\u201360.","journal-title":"Expert Rev Hematol"},{"key":"8196_CR75","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01973-5","volume":"23","author":"A Zingoni","year":"2024","unstructured":"Zingoni A, Antonangeli F, Sozzani S, Santoni A, Cippitelli M, Soriani A. The senescence journey in cancer immunoediting. Mol Cancer. 2024;23:68.","journal-title":"Mol Cancer"},{"key":"8196_CR76","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","volume":"113","author":"A Soriani","year":"2009","unstructured":"Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood. 2009;113:3503\u201311.","journal-title":"Blood"},{"key":"8196_CR77","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1400271","volume":"193","author":"A Soriani","year":"2014","unstructured":"Soriani A, Iannitto ML, Ricci B, Fionda C, Malgarini G, Morrone S, et al. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. J Immunol. 2014;193:950\u201360.","journal-title":"J Immunol"},{"key":"8196_CR78","doi-asserted-by":"crossref","unstructured":"Metge BJ, Williams L, Swain CA, Hinshaw DC, Elhamamsy AR, Chen D, et al. Ribosomal RNA biosynthesis functionally programs tumor-associated macrophages to support breast cancer progression. Cancer Res. 2025;85:1459\u201378.","DOI":"10.1158\/0008-5472.CAN-24-0707"},{"key":"8196_CR79","doi-asserted-by":"publisher","first-page":"100856","DOI":"10.1016\/j.neo.2022.100856","volume":"35","author":"SY Chung","year":"2023","unstructured":"Chung SY, Chang YC, Hsu DS, Hung YC, Lu ML, Hung YP, et al. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer. Neoplasia. 2023;35:100856.","journal-title":"Neoplasia"},{"key":"8196_CR80","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41416-025-03109-y","volume":"133","author":"K Cui","year":"2025","unstructured":"Cui K, Liu B, Gong L, Wan Q, Tang H, Gong Z, et al. Targeting ribosomes reprograms the tumour microenvironment and augments cancer immunotherapy. Br J Cancer. 2025;133:756\u201370.","journal-title":"Br J Cancer"},{"key":"8196_CR81","doi-asserted-by":"publisher","first-page":"106120","DOI":"10.1016\/j.phrs.2022.106120","volume":"177","author":"G Pan","year":"2022","unstructured":"Pan G, Zhang J, Han Y, Chen Y, Guo X, Cui X, et al. CX-5461 is a potent immunosuppressant which inhibits T cell-mediated alloimmunity via p53-DUSP5. Pharmacol Res. 2022;177:106120.","journal-title":"Pharmacol Res"},{"key":"8196_CR82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.20221941","volume":"220","author":"W He","year":"2023","unstructured":"He W, Gea-Mallorqui E, Colin-York H, Fritzsche M, Gillespie GM, Brackenridge S, et al. Intracellular trafficking of HLA-E and its regulation. J Exp Med. 2023;220:1\u201318.","journal-title":"J Exp Med"},{"key":"8196_CR83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41588-023-01602-9","volume":"56","author":"GCC Koh","year":"2024","unstructured":"Koh GCC, Boushaki S, Zhao SJ, Pregnall AM, Sadiyah F, Badja C, et al. The chemotherapeutic drug CX-5461 is a potent mutagen in cultured human cells. Nat Genet. 2024;56:23\u201326.","journal-title":"Nat Genet"},{"key":"8196_CR84","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2013.12.009","volume":"25","author":"K Peltonen","year":"2014","unstructured":"Peltonen K, Colis L, Liu H, Trivedi R, Moubarek MS, Moore HM, et al. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. Cancer Cell. 2014;25:77\u201390.","journal-title":"Cancer Cell"},{"key":"8196_CR85","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1158\/1535-7163.MCT-14-0256","volume":"13","author":"K Peltonen","year":"2014","unstructured":"Peltonen K, Colis L, Liu H, Jaamaa S, Zhang Z, Af Hallstrom T, et al. Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. Mol Cancer Ther. 2014;13:2537\u201346.","journal-title":"Mol Cancer Ther"},{"key":"8196_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14225544","volume":"14","author":"RQ Jacobs","year":"2022","unstructured":"Jacobs RQ, Fuller KB, Cooper SL, Carter ZI, Laiho M, Lucius AL, et al. RNA Polymerase I is uniquely vulnerable to the small-molecule inhibitor BMH-21. Cancers. 2022;14:1\u201314.","journal-title":"Cancers"},{"key":"8196_CR87","doi-asserted-by":"publisher","first-page":"101450","DOI":"10.1016\/j.jbc.2021.101450","volume":"298","author":"RQ Jacobs","year":"2022","unstructured":"Jacobs RQ, Huffines AK, Laiho M, Schneider DA. The small-molecule BMH-21 directly inhibits transcription elongation and DNA occupancy of RNA polymerase I in vivo and in vitro. J Biol Chem. 2022;298:101450.","journal-title":"J Biol Chem"},{"key":"8196_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2024.09.010","volume":"6","author":"M Saetersmoen","year":"2025","unstructured":"Saetersmoen M, Kotchetkov IS, Torralba-Raga L, Mansilla-Soto J, Sohlberg E, Krokeide SZ, et al. Targeting HLA-E-overexpressing cancers with a NKG2A\/C switch receptor. Med. 2025;6:100521.","journal-title":"Med"},{"key":"8196_CR89","doi-asserted-by":"publisher","first-page":"4385","DOI":"10.4049\/jimmunol.0901797","volume":"183","author":"C Fionda","year":"2009","unstructured":"Fionda C, Soriani A, Malgarini G, Iannitto ML, Santoni A, Cippitelli M. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. J Immunol. 2009;183:4385\u201394.","journal-title":"J Immunol"},{"key":"8196_CR90","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/s41419-023-05949-z","volume":"14","author":"S Petillo","year":"2023","unstructured":"Petillo S, Sproviero E, Loconte L, Cuollo L, Zingoni A, Molfetta R, et al. NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells. Cell Death Dis. 2023;14:438.","journal-title":"Cell Death Dis"},{"key":"8196_CR91","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1038\/nprot.2009.191","volume":"4","author":"F Debacq-Chainiaux","year":"2009","unstructured":"Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc. 2009;4:1798\u20131806.","journal-title":"Nat Protoc"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08196-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08196-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:02:48Z","timestamp":1764345768000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08196-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8196"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08196-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Healthy donors were recruited by the Blood Transfusion Centre of \u201cPoliclinico Umberto I\u201d Hospital (Rome, Italy) in anonymized form and gave written informed consent. All the procedures involving participants were in accordance with the declaration of Helsinki. The study was approved by the Ethics Committee of Sapienza University of Rome (approval number 639\/16 RIF\/CE 4179). Bone marrow samples from patients with MM were managed at the Division of Hematology, Department of Cellular Biotechnologies and Hematology, University of Rome, La Sapienza, Rome, Italy. Informed consent in accordance with the Declaration of Helsinki was obtained from all patients, and approval was obtained from the Ethics Committee of the Sapienza University of Rome (RIF. 5191 and 639\/16 RIF\/CE 4179).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"865"}}